Literature DB >> 3917716

Convulsions associated with cyclosporin A in renal transplant recipients.

M Beaman, S Parvin, P S Veitch, J Walls.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3917716      PMCID： PMC1415508          DOI： 10.1136/bmj.290.6462.139

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN： 0267-0623


× No keyword cloud information.
  5 in total

1.  Hypertension and convulsions in children receiving cyclosporin A.

Authors:  D V Joss; A J Barrett; J R Kendra; C F Lucas; S Desai
Journal:  Lancet       Date:  1982-04-17       Impact factor: 79.321

2.  Cyclosporine-associated central-nervous-system toxicity after allogeneic bone-marrow transplantation.

Authors:  K Atkinson; J Biggs; P Darveniza; J Boland; A Concannon; A Dodds
Journal:  N Engl J Med       Date:  1984-02-23       Impact factor: 91.245

3.  Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers.

Authors:  R Y Calne; K Rolles; D J White; S Thiru; D B Evans; P McMaster; D C Dunn; G N Craddock; R G Henderson; S Aziz; P Lewis
Journal:  Lancet       Date:  1979-11-17       Impact factor: 79.321

4.  Cyclosporin A in patients receiving renal allografts from cadaver donors.

Authors:  R Y Calne; D J White; S Thiru; D B Evans; P McMaster; D C Dunn; G N Craddock; B D Pentlow; K Rolles
Journal:  Lancet       Date:  1978 Dec 23-30       Impact factor: 79.321

5.  Cyclosporin A to prevent graft-versus-host disease in man after allogeneic bone-marrow transplantation.

Authors:  R L Powles; H M Clink; D Spence; G Morgenstern; J G Watson; P J Selby; M Woods; A Barrett; B Jameson; J Sloane; S D Lawler; H E Kay; D Lawson; T J McElwain; P Alexander
Journal:  Lancet       Date:  1980-02-16       Impact factor: 79.321
  5 in total
  6 in total

1.  Variable incidence of cyclosporine and FK-506 neurotoxicity in hematopoeitic malignancies and marrow conditions after allogeneic bone marrow transplantation.

Authors:  Walter S Bartynski; Zella R Zeigler; Richard K Shadduck; John Lister
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

2.  Etiology of cortical and white matter lesions in cyclosporin-A and FK-506 neurotoxicity.

Authors:  W S Bartynski; Z Zeigler; M P Spearman; L Lin; R K Shadduck; J Lister
Journal:  AJNR Am J Neuroradiol       Date:  2001 Nov-Dec       Impact factor: 3.825

Review 3.  The pathophysiology of Sandimmune (cyclosporine) in man and animals.

Authors:  J Mason
Journal:  Pediatr Nephrol       Date:  1990-11       Impact factor: 3.714

4.  Complex partial status epilepticus associated with cyclosporin A therapy.

Authors:  R E Appleton; K Farrell; P Teal; S A Hashimoto; P K Wong
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-09       Impact factor: 10.154

5.  Pretransplantation conditioning influence on the occurrence of cyclosporine or FK-506 neurotoxicity in allogeneic bone marrow transplantation.

Authors:  Walter S Bartynski; Zella R Zeigler; Richard K Shadduck; John Lister
Journal:  AJNR Am J Neuroradiol       Date:  2004-02       Impact factor: 3.825

Review 6.  Clinical pharmacokinetics of cyclosporin.

Authors:  R J Ptachcinski; R Venkataramanan; G J Burckart
Journal:  Clin Pharmacokinet       Date:  1986 Mar-Apr       Impact factor: 6.447
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.